Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Selinexor (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 06 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 07 Jun 2018 Planned End Date changed from 1 Oct 2018 to 1 Jan 2020.